newsfilter
← Earnings
Earnings Releases·

Adagio Medical — Third Quarter 2026 Earnings Summary

  • Reported net income of $17.8 million ($2.40 per basic share) for Q3 2026, a significant turnaround from a $10.1 million net loss in Q3 2025, primarily driven by a $23.0 million noncash gain on the change in fair value of Senior Secured Convertible Notes; diluted net loss per share was $(5.13) excluding this gain.
  • Revenue remained at $0 for the quarter as commercial activity in Europe paused, while operating expenses declined with R&D dropping to $1.8 million and SG&A falling to $2.6 million compared to prior year levels.
  • The Board initiated a formal process to explore strategic alternatives to maximize shareholder value, and the Company executed a 1-for-30 reverse stock split on November 6, 2026, to regain Nasdaq compliance.
  • The FULCRUM-VT pivotal study is fully enrolled with 209 patients, and the FDA granted IDE approval to expand the trial to evaluate the next-generation vCLAS Ultra catheter, which treated 22 patients across the U.S. and Canada during the quarter.
  • Liquidity decreased with cash and cash equivalents falling to $3.1 million as of September 30, 2026, from $17.1 million at year-end 2025, while total stockholder's equity increased to $18.4 million.
Company
ADAGIO MEDICAL HOLDINGS INC
Sector
Healthcare
Industry
Medical Devices